Letter Urging Prohibition of Pharmacy Benefit Managers from Owning or Operating Pharmacies

The letter urges Congress to pass legislation prohibiting PBMs and their parent companies from owning or operating pharmacies to foster fair competition and protect consumers

Read More →

United States and Plaintiff States v. Live Nation Entertainment et al (S.D.N.Y. 1:24-CV-03973-AS)

Forty attorneys general joined the U.S. Department of Justice in a lawsuit against Live Nation Entertainment, Inc. and its subsidiary, Ticketmaster L.L.C.  The lawsuit alleges that Live Nation has undertaken anticompetitive conduct in various markets across the live concert ecosystem to maintain its monopoly positions in the markets for primary ticketing services for major concert…

Read More →

State and Territory Attorneys General Urge FDA to Take Action Against Counterfeit and Illegally Sold GLP-1 Drugs

Washington, D.C.– The National Association of Attorneys General (NAAG) sent a letter on behalf of a bipartisan coalition of 38 state and territory attorneys general which calls on the Food and Drug Administration (FDA) to take decisive action against the unlawful sale and distribution of counterfeit and illegally sold GLP-1 drugs, including Mounjaro, Zepbound, Ozempic, and…

Read More →

A Bipartisan Coalition of 47 Attorneys General Call on the FCC to Strengthen the Robocall Mitigation Database

To strengthen the Robocall Mitigation Database (RMD) so that providers understand what information they need to submit and have deadlines to submit this information

Read More →

A Bipartisan Coalition of 39 State Attorneys General Urge Congressional Action on Pharmacy Benefit Manager Reform

The National Association of Attorneys General (NAAG) sent a letter to Congressional leaders on behalf of 39 attorneys general who urge congressional leaders to engage in meaningful debate and reform of the current practices of pharmacy benefit managers (PBMs) and to take decisive action to reform the way PBMs conduct business and bring more transparency…

Read More →

45 State Attorneys General Join in their Ongoing Efforts to Protect Consumers from Robocalls

A bi-partisan coalition of 45 state attorneys general sent a letter to the Federal Communications Commission (FCC) seeking to safeguard consumers from scam phone calls made by Voice-Over-Internet-Protocol (VoIP) service providers. The attorneys general submitted comments to the FCC on its proposal “to safeguard and secure the open Internet” (NPRM) asking it to clarify that…

Read More →

Ohio et al. v. National Collegiate Athletic Association (NCAA), No. 1:23-cv-00100 (N.D. W.V. Dec. 7, 2023)

Seven plaintiff states filed suit against the NCAA in 2023, alleging that the NCAA’s transfer eligibility rule is an illegal restraint on college athletes’ ability to market their labor and control their education.  The rule requires college athletes who transfer among Division 1 schools to wait one year before competing in games, unless they obtain…

Read More →

Bipartisan Coalition of Attorneys General Express Support for the G.U.A.R.D. VA Act

A bipartisan coalition of 44 attorneys general express support for the passage of legislative proposals included in Governing Unaccredited Representatives Defrauding (G.U.A.R.D.) Veterans Affairs (VA) Benefits Act. In a letter to congressional leaders, the attorneys general explain that the passing of the bipartisan legislation would hold unaccredited and unregulated actors accountable for targeting and preying…

Read More →

Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)

44 plaintiff states filed suit against Teva Pharmaceuticals and 19 of the nation’s largest generic drug manufacturers alleging a broad conspiracy to artificially inflate and manipulate prices, reduce competition and unreasonably restrain trade for more than 100 different generic drugs. The lawsuit was originally Connecticut, was transferred to the MDL court in Pennsylvania.  The lawsuit…

Read More →

Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)

Plaintiff states filed a third lawsuit stemming from the ongoing antitrust investigation into a widespread conspiracy by generic drug manufacturers to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for generic drugs sold across the United States. The complaint focuses on 80 topical generic drugs  and names 26 corporate Defendants and 10…

Read More →